X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4227) 4227
Magazine Article (24) 24
Newspaper Article (4) 4
Book Chapter (3) 3
Book Review (2) 2
Newsletter (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3087) 3087
muscular diseases - chemically induced (2860) 2860
male (1834) 1834
animals (1494) 1494
female (1479) 1479
middle aged (929) 929
adult (884) 884
aged (620) 620
muscular diseases - pathology (602) 602
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (587) 587
rats (513) 513
mice (477) 477
myopathy (387) 387
pharmacology & pharmacy (334) 334
skeletal-muscle (334) 334
neurosciences (331) 331
muscle, skeletal - drug effects (320) 320
muscle, skeletal - pathology (314) 314
statins (311) 311
medicine, general & internal (304) 304
clinical neurology (295) 295
muscular diseases - diagnosis (273) 273
risk factors (272) 272
disease models, animal (268) 268
creatine kinase - blood (266) 266
muscles (266) 266
proteins (255) 255
muscle, skeletal - metabolism (252) 252
adolescent (245) 245
muscles - pathology (245) 245
muscular diseases - physiopathology (240) 240
time factors (224) 224
cell biology (215) 215
pain - chemically induced (215) 215
therapy (210) 210
muscular diseases - metabolism (209) 209
expression (208) 208
skeletal muscle (208) 208
research (200) 200
muscular system (190) 190
muscular atrophy - chemically induced (188) 188
biochemistry & molecular biology (184) 184
rhabdomyolysis (184) 184
dose-response relationship, drug (183) 183
muscular dystrophy (183) 183
physiology (183) 183
rodents (176) 176
child (173) 173
syndrome (172) 172
muscle (167) 167
research article (164) 164
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (158) 158
biopsy (157) 157
rhabdomyolysis - chemically induced (157) 157
drug interactions (152) 152
musculoskeletal system (151) 151
analysis (149) 149
electromyography (149) 149
health aspects (149) 149
muscular diseases - epidemiology (149) 149
muscular diseases - prevention & control (149) 149
muscular diseases - complications (147) 147
aged, 80 and over (144) 144
muscular diseases - genetics (144) 144
medicine, research & experimental (142) 142
muscular diseases - drug therapy (142) 142
eosinophilia - chemically induced (141) 141
disease (139) 139
duchenne muscular-dystrophy (139) 139
treatment outcome (139) 139
necrosis (138) 138
physiological aspects (137) 137
cardiac & cardiovascular systems (136) 136
safety (132) 132
simvastatin (132) 132
toxicology (132) 132
atrophy (131) 131
mice, inbred c57bl (129) 129
tryptophan - adverse effects (129) 129
abridged index medicus (128) 128
gene expression (127) 127
muscles - drug effects (125) 125
mutation (125) 125
muscular diseases - etiology (124) 124
muscle, skeletal - physiopathology (122) 122
microscopy, electron (120) 120
risk (117) 117
rats, sprague-dawley (116) 116
cholesterol (115) 115
cells, cultured (113) 113
anticholesteremic agents - adverse effects (112) 112
muscular diseases - enzymology (112) 112
medicine (110) 110
rats, wistar (110) 110
care and treatment (108) 108
succinylcholine - adverse effects (108) 108
complications and side effects (107) 107
regeneration (106) 106
toxicity (106) 106
pathology (105) 105
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3757) 3757
French (146) 146
German (113) 113
Japanese (68) 68
Spanish (66) 66
Italian (30) 30
Russian (27) 27
Danish (15) 15
Swedish (15) 15
Polish (12) 12
Chinese (10) 10
Norwegian (7) 7
Dutch (6) 6
Czech (5) 5
Hebrew (5) 5
Portuguese (5) 5
Finnish (4) 4
Hungarian (4) 4
Korean (3) 3
Croatian (2) 2
Serbian (2) 2
Slovak (2) 2
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 2016, Volume 67, Issue 20, pp. 2395 - 2410
.... SAMS is the most frequent SAS, and mild myalgia may affect 5% to 10% of statin users. Clinically important muscle symptoms, including rhabdomyolysis and statin-induced necrotizing autoimmune myopathy... 
Cardiovascular | Internal Medicine | rhabdomyolysis | skeletal muscle | interstitial lung disease | myopathy | C-REACTIVE PROTEIN | RANDOMIZED CONTROLLED-TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | FORCE 2014 UPDATE | PRIMARY-PREVENTION TRIAL | INDUCED MUSCLE TOXICITY | INTERSTITIAL LUNG-DISEASE | CENTRAL-NERVOUS-SYSTEM | OF-THE-LITERATURE | CORONARY-HEART-DISEASE | TYPE-2 DIABETES-MELLITUS | Liver Function Tests | Sleep Wake Disorders - chemically induced | Hydroxymethylglutaryl-CoA Reductase Inhibitors - immunology | Myalgia - chemically induced | Humans | Hyperlipidemias - drug therapy | Risk Factors | Lung Diseases, Interstitial - chemically induced | Tendon Injuries - chemically induced | Necrosis - chemically induced | Brain - drug effects | Rupture - chemically induced | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Stroke - chemically induced | Cognition Disorders - etiology | Depression - chemically induced | Rhabdomyolysis - chemically induced | Antibodies - blood | Diabetes Mellitus - chemically induced | Acute Kidney Injury - chemically induced | Muscular Diseases - chemically induced | Testosterone - blood | Autoimmune Diseases - chemically induced | Hyperlipidemias - complications | Viral antibodies | Complications and side effects | Enzymes | Thiols | Antibodies | Diabetes | Cardiology | Statins | Cardiovascular agents | Creatine kinase | Muscles | Creatine | Respiratory tract diseases | Studies | Musculoskeletal system | Genotype & phenotype | Mortality | Clinical trials | Lipids | Clinical medicine
Journal Article
BMJ : British Medical Journal, ISSN 1756-1833, 7/2014, Volume 349, Issue jul17 11, pp. g3743 - g3743
Statins form the pharmacologic cornerstone of the primary and secondary prevention of atherosclerotic cardiovascular disease... 
STATE OF THE ART REVIEW | LDL CHOLESTEROL | ACUTE KIDNEY INJURY | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | PULMONARY-HYPERTENSION | RANDOMIZED CONTROLLED-TRIAL | PLACEBO-CONTROLLED TRIAL | CORONARY-HEART-DISEASE | AVERAGE CHOLESTEROL LEVELS | OF-THE-LITERATURE | ERECTILE DYSFUNCTION | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Meta-Analysis as Topic | Cataract - chemically induced | Erectile Dysfunction - chemically induced | Humans | Male | Fatigue - chemically induced | Pancreatitis - prevention & control | Hypercholesterolemia - drug therapy | Transaminases - analysis | Organic Anion Transporters - genetics | Contrast Media - adverse effects | Neoplasms - chemically induced | Kidney Diseases - chemically induced | Acute Kidney Injury - chemically induced | Muscular Diseases - chemically induced | Genetic Predisposition to Disease | Kidney Diseases - prevention & control | Risk Factors | Clinical Trials as Topic | Cognition - drug effects | Liver - chemistry | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Dementia - chemically induced | Venous Thromboembolism - chemically induced | Diabetes Mellitus - chemically induced | Chemical and Drug Induced Liver Injury | Polymorphism, Single Nucleotide | Muscular Diseases - genetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Research Design | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Journal Article
Journal Article
by Meade, T and Collins, R and Armitage, J and Parish, S and Barton, J and Bray, C and Wincott, E and Bowman, L and Clarke, R and Graham, I and Simpson, D and Warlow, C and Tobert, J and Musliner, T and Doll, R and Fox, K.M and Hill, C and Sandercock, P and Peto, R and Webster, J and Jamieson, J and Nixon, A and Lackie, S and Thompson, J and Brown, M and Blackwood, S and Morgan, M and Rhoden, W and Saeed, B and Houghton, M and Nicholson, A and Simpson, C and Hoburn, B and Cooper, I and Gallivan, A and Pickerell, E and Hancock, J and Watkinson, J and Burbridge, W and Kitchen, M and O'Leary, H and Verow, C and Meynell, L and Rollinson, L and Bain, S and Jones, A and Jewkes, C and Russon, C and Bateson, M and Gill, P and Stansbie, D and Bayly, G and Andrews, G and Halestrap, M and Meredith, J and Best, R and Appleyard, D and Wareing, H and Holmes, K and Holt, J and Kenyon, M and White, C and Khalifa, M and Newton, D and Wass, A and Watkinson, R and Creamer, J and Bethell, A and Butler, C and Washington, M and Weston, E and Machin, J and Cleaver, K and Wray, R and Sinclair, J and Van Aalst, A and Been, M and Mattu, R and Burke, A and Gill, L and Walton, E and Cowley, M and Robson, H and Graham, A and Rose, G and Kerr, M and Mallinson, J and Peascod, B and Scott, A and Donnelly, R and Gibson, T and Hannah, J and Henshaw, L and Margetts, M and Pearson, N and Frost, S and Murray, S and Marshall, A and Went, J and Simmonds, J and ... and unav and The SEARCH Collaborative Group and SEARCH Collaborative Grp and SEARCH Collaborative Group and Sahlgrenska akademin and Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin and Institute of Medicine, Department of Emergeny and Cardiovascular Medicine and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The New England journal of medicine, ISSN 1533-4406, 2008, Volume 359, Issue 8, pp. 789 - 799
A genomewide association study was conducted to determine the common variants that are associated with an increased risk of statin-induced myopathy... 
MEDICINE, GENERAL & INTERNAL | POLYMORPHISMS | EFFICACY | SAFETY | TRANSPORTING POLYPEPTIDE 1B1 | SIMVASTATIN | CYP3A4 | ASSOCIATION | ATORVASTATIN | Simvastatin - therapeutic use | Simvastatin - adverse effects | Humans | Middle Aged | Diabetes Mellitus - drug therapy | Genotype | Male | Risk | Genetic Markers | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Myocardial Infarction - drug therapy | Arterial Occlusive Diseases - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Female | Aged | Myocardial Infarction - prevention & control | Polymorphism, Single Nucleotide | Chromosomes, Human, Pair 12 | Muscular Diseases - chemically induced | Muscular Diseases - genetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Complications and side effects | Analysis | Muscle diseases | Genetic aspects | Dosage and administration | Single nucleotide polymorphisms | Risk factors | Statins | Drug therapy | Kinases | Drug dosages | Cholesterol | Index Medicus | Abridged Index Medicus | MEDICIN OCH HÄLSOVETENSKAP | Single Nucleotide | genetics | Arterial Occlusive Diseases | pharmacokinetics | Muscular Diseases | Hydroxymethylglutaryl-CoA Reductase Inhibitors | Chromosomes | MEDICAL AND HEALTH SCIENCES | Human | drug therapy | chemically induced | Simvastatin | prevention & control | Diabetes Mellitus | Myocardial Infarction | Pair 12 | Organic Anion Transporters | adverse effects | therapeutic use | Polymorphism
Journal Article
Critical Care Medicine, ISSN 0090-3493, 06/2010, Volume 38 Suppl, Identification and Prevention of Common Adverse Drug Events in the Intensive Care Unit, Issue 6, pp. S231 - S243
As critically ill patients frequently receive analgesics, sedatives, and antipsychotics to optimize patient comfort and facilitate mechanical ventilation,... 
Coma | Delirium | Dverse drug events | Benzodiazepine | Critical care | Fentanyl | Opioid | Pharmacology | Haloperidol | Drug safety | Intensive care unit | Prevention | Analgesic | Dexmedetomidine | Antipsychotic | Lorazepam | Midazolam | Propofol | Sedative | dexmedetomidine | analgesic | propofol | critical care | QTC INTERVAL | MECHANICALLY VENTILATED PATIENTS | haloperidol | PROPOFOL INFUSION SYNDROME | midazolam | fentanyl | pharmacology | antipsychotic | intensive care unit | LONG-TERM SEDATION | sedative | delirium | prevention | benzodiazepine | CRITICAL CARE MEDICINE | drug safety | opioid | lorazepam | coma | ATYPICAL ANTIPSYCHOTICS | HIGH-DOSE DEXMEDETOMIDINE | adverse drug events | HUMAN NEUTROPHIL FUNCTIONS | TORSADE-DE-POINTES | PROPYLENE-GLYCOL TOXICITY | CRITICALLY-ILL PATIENTS | Critical Care - methods | Drug-Related Side Effects and Adverse Reactions - prevention & control | Hypnotics and Sedatives - adverse effects | Drug-Related Side Effects and Adverse Reactions - chemically induced | Endocrine System Diseases - chemically induced | United States | Antipsychotic Agents - adverse effects | Humans | Excipients - adverse effects | Fatty Liver - chemically induced | Infection - etiology | Muscular Diseases - chemically induced | Propofol - administration & dosage | Analgesics - adverse effects | Intensive Care Units | Infection - immunology | Acidosis - chemically induced | Substance Withdrawal Syndrome | Syndrome | Bradycardia - chemically induced | Immune System - drug effects | Nervous System Diseases - chemically induced | Cardiovascular Diseases - chemically induced | Infusions, Intravenous | Hyperlipidemias - chemically induced | Drug-Related Side Effects and Adverse Reactions - physiopathology | Gastrointestinal Diseases - chemically induced | Propofol - adverse effects | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 12/2012, Volume 308, Issue 23, pp. 2497 - 2506
Journal Article